| Literature DB >> 31728168 |
José Brango-Vanegas1, Luan A Martinho1, Lucinda J Bessa2, Andreanne G Vasconcelos3, Alexandra Plácido4,5, Alex L Pereira6, José R S A Leite3, Angelo H L Machado1.
Abstract
Eight new sulfide-based cyclic peptidomimetic analogues of solonamides A and B have been synthesized via solid-phase peptide synthesis and SN2' reaction on a Morita-Baylis-Hillman (MBH) residue introduced at the N-terminal of a tetrapeptide. This last step takes advantage of the electrophilic feature of the MBH residue and represents a new cyclization strategy occurring. The analogues were prepared in moderate overall yields and did not show toxic effects on Staphylococcus aureus growth and were not toxic to human fibroblasts. Two of them inhibited the hemolytic activity of S. aureus, suggesting an interfering action in the bacterial quorum sensing similar to the one already reported for solonamides.Entities:
Keywords: antivirulence drug; bacteria; macrocyclization; pathoblocker; quorum quenching
Year: 2019 PMID: 31728168 PMCID: PMC6839570 DOI: 10.3762/bjoc.15.247
Source DB: PubMed Journal: Beilstein J Org Chem ISSN: 1860-5397 Impact factor: 2.883
Figure 1Chemical structure of solonamides and autoinducing peptides (AIP).
Scheme 1Macrocyclization strategy based on SN2’.
Scheme 2Chemical synthesis of the MBH adducts 2 and their carboxylic acids 3.
Scheme 3Chemical synthesis of the linear peptidomimetics 8.
Scheme 4Macrocyclization strategy based on SN2’ reaction to affords the solonamide analogues 9 and their overall yields based on the initial resin’s molarity.
Halos of hemolysis or inhibition of hemolysis of S. aureus ATCC 25923 on sheep blood agar plates (Assay 2).a
| Analogue | 20 mM | 1 mM | 200 μM |
| + | + | + | |
| + | + | + | |
| + | + | + | |
| + | + | + | |
| – | – | – | |
| + | + | + | |
| – | +* | +* | |
| – | + | + | |
a(+): Hemolysis halo; (–): no hemolysis halo; *visibly smaller hemolysis halo when compared to controls.
Figure 2Effect of compounds 9e and 9g at three concentrations on the hemolysis production by S. aureus ATCC 25923 (Assay 2, Inoc = inoculum). Regarding compound 9e, no hemolysis halo was observed around the bacterial spot.
Figure 3Inhibition of hemolysis (%) on human red blood cells caused by S. aureus ATCC 25923 after being in presence of several concentrations of compounds 9e and 9g (assay 3). The hemolysis is scored in % of hemolysis relative to the control (hemolysis caused by S. aureus ATCC 25923 in absence of any compound; only DMSO), which was set to 100%. Two independent experiments were performed in duplicate. Error bars represent standard deviations.
Figure 4Cell viability of human fibroblast exposed to compounds 9e (A) and 9g (B) for 24 and 48 hours. The values are expressed as mean ± SEM. ****p < 0.0001, **p < 0.005 and ***p < 0.001 versus DMEM control group.